California Public Employees Retirement System lowered its stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 5.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,800 shares of the company’s stock after selling 4,800 shares during the period. California Public Employees Retirement System’s holdings in Anika Therapeutics were worth $4,201,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in ANIK. Teacher Retirement System of Texas increased its position in Anika Therapeutics by 14.1% in the second quarter. Teacher Retirement System of Texas now owns 2,037 shares of the company’s stock valued at $109,000 after buying an additional 252 shares in the last quarter. BlackRock Inc. increased its position in Anika Therapeutics by 99.0% in the second quarter. BlackRock Inc. now owns 2,032 shares of the company’s stock valued at $109,000 after buying an additional 1,011 shares in the last quarter. Mason Street Advisors LLC bought a new position in Anika Therapeutics during the second quarter valued at $150,000. Paloma Partners Management Co bought a new position in Anika Therapeutics during the second quarter valued at $233,000. Finally, Bank of Montreal Can bought a new position in Anika Therapeutics during the second quarter valued at $247,000. 76.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) traded down 1.14% during trading on Monday, reaching $46.10. The company’s stock had a trading volume of 119,998 shares. The stock has a 50 day moving average of $44.63 and a 200-day moving average of $47.79. The company has a market capitalization of $674.12 million, a PE ratio of 19.78 and a beta of 1.68. Anika Therapeutics Inc. has a 1-year low of $35.07 and a 1-year high of $54.96.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, October 26th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.47 by $0.12. Anika Therapeutics had a return on equity of 17.21% and a net margin of 33.64%. The company had revenue of $25.79 million for the quarter, compared to analyst estimates of $26.60 million. During the same period last year, the company earned $0.55 earnings per share. Anika Therapeutics’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, analysts expect that Anika Therapeutics Inc. will post $2.15 earnings per share for the current year.
Separately, Zacks Investment Research downgraded Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 11th.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.